Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).Narcolepsy type 2, also known as narcolepsy without cataplexy, is a sleep disorder characterized by excessive daytime sleepiness (EDS). Unlike type 1, it typically does not include cataplexy (sudden muscle weakness triggered by emotions).In the trial, once-daily alixorexton met the dual primary endpoints, demonstrating statisti ...

Alkermes (NasdaqGS:ALKS) Update / Briefing November 12, 2025 08:30 AM ET Speaker2Greetings and welcome to the Alkermes conference call. My name is Rob, and I'll be your operator for today's call. All participants will be placed on mute to prevent background noise. If you should require operator assistance during the call, please press star zero on your telephone keypad. Please note that this conference is being recorded. I'll now turn the call over to Sandra Coombs, Senior Vice President of Investor Relatio ...

Core Insights - Alkermes announced that its experimental drug for narcolepsy successfully met the primary objectives in a mid-stage clinical trial [1] Company Summary - The company is advancing its research in the treatment of narcolepsy, indicating progress in its drug development pipeline [1]

Accessibility StatementSkip Navigation "The alixorexton data from Vibrance-2 are the first demonstration in a large, randomized phase 2 study that an orexin 2 receptor agonist can drive clinically meaningful improvements in wakefulness and excessive daytime sleepiness in patients without known orexin deficiency, with a generally well tolerated profile. These data are exciting and represent an important breakthrough in advancing a potential new treatment option for patients living with narcolepsy type 2," sa ...

Core Insights - Alkermes (ALKS) is currently viewed as a better value opportunity compared to Illumina (ILMN) based on various financial metrics and rankings [1][7] Valuation Metrics - Alkermes has a Zacks Rank of 1 (Strong Buy), indicating a positive earnings outlook, while Illumina has a Zacks Rank of 3 (Hold) [3] - The forward P/E ratio for Alkermes is 16.69, significantly lower than Illumina's forward P/E of 25.86, suggesting that Alkermes may be undervalued [5] - Alkermes has a PEG ratio of 1.36, compared to Illumina's PEG ratio of 2.62, indicating a more favorable valuation relative to expected earnings growth [5] - The P/B ratio for Alkermes is 3.11, while Illumina's P/B ratio is 7.81, further supporting the notion that Alkermes is undervalued [6] - Based on these metrics, Alkermes has earned a Value grade of B, whereas Illumina has a Value grade of C [6] Earnings Outlook - Alkermes is noted for its improving earnings outlook, which enhances its attractiveness as a value investment [7]

Core Insights - Top Wall Street analysts have revised their outlook on several prominent companies, indicating a shift in market sentiment and potential investment opportunities [1] Company Analysis - Analysts are considering buying ALKS stock, suggesting a positive outlook for the company [1]

Group 1: Company Performance - Alkermes (ALKS) has shown a year-to-date performance increase of approximately 8%, outperforming the average return of 1.3% for Medical companies [4] - The Zacks Consensus Estimate for ALKS' full-year earnings has risen by 14.7% over the past 90 days, indicating a positive trend in analyst sentiment [3] - Alkermes holds a Zacks Rank of 1 (Strong Buy), suggesting strong potential for future performance [3] Group 2: Industry Context - Alkermes is part of the Medical - Biomedical and Genetics industry, which consists of 469 stocks and currently ranks 99 in the Zacks Industry Rank [5] - The Medical - Biomedical and Genetics industry has experienced an average gain of 11.4% this year, indicating that Alkermes is slightly underperforming its industry [5] - In contrast, Cardinal Health, which belongs to the Medical - Dental Supplies industry, has returned 66.4% year-to-date and has a Zacks Rank of 2 (Buy) [4][5]

Core Insights - Alkermes plc is a biopharmaceutical company focused on central nervous system disorders, with significant R&D efforts led by Craig C. Hopkinson, who recently sold 9,000 shares but still retains 69,740 shares, indicating continued investment in the company [1] Strategic Moves - Alkermes is expanding its portfolio through the acquisition of Avadel Pharmaceuticals plc for approximately $2.1 billion, which includes the FDA-approved drug Lumryz, marking its entry into the sleep medicine market [2] - The acquisition involves an immediate payment of $18.50 per share, with an additional $1.50 contingent on FDA approval of Lumryz for idiopathic hypersomnia by 2028, expected to close in the first quarter of 2026 [3] Financial Metrics - Alkermes has a P/E ratio of 14.70, indicating positive market valuation of its earnings, with a price-to-sales ratio of 3.27 and an enterprise value to sales ratio of 2.92, reflecting strong revenue and sales valuation [4] - The company maintains a low debt-to-equity ratio of 0.041, showcasing a conservative approach to debt, and a strong current ratio of 3.67, indicating its ability to cover short-term liabilities [5] - Alkermes offers an earnings yield of 6.80%, providing a solid return on investment for shareholders [5]

Core Insights - Alkermes plc reported earnings from continuing operations of 49 cents per share for Q3 2025, exceeding the Zacks Consensus Estimate of 42 cents and down from 56 cents per share in the same quarter last year [1][8] - Total revenues for the third quarter reached $394.2 million, a 4% increase year-over-year, significantly surpassing the Zacks Consensus Estimate of $355.7 million [1][8] Revenue Breakdown - Alkermes' proprietary products, including Vivitrol, Aristada, and Lybalvi, generated total sales of $317.4 million, reflecting a 16% year-over-year growth, driven by strong demand [3][4] - Vivitrol sales increased by 7% year-over-year to $121.1 million, exceeding the Zacks Consensus Estimate of $112.1 million [5] - Aristada sales rose 16% year-over-year to $98.1 million, surpassing the Zacks Consensus Estimate of $87 million [6] - Lybalvi achieved sales of $98.2 million, a 32% increase year-over-year, also beating the Zacks Consensus Estimate of $87.1 million [7] Financial Guidance - Alkermes raised its 2025 revenue guidance to a range of $1.43 billion to $1.49 billion, up from the previous range of $1.34 billion to $1.43 billion [13] - The company expects Vivitrol net sales to be between $460 million and $470 million, Aristada sales between $360 million and $370 million, and Lybalvi sales between $340 million and $350 million for the full year [14] Strategic Developments - Alkermes announced a definitive agreement to acquire Avadel Pharmaceuticals for up to $20.00 per share, totaling approximately $2.1 billion, expected to close in Q1 2026 [15] - The acquisition will enhance Alkermes' portfolio with Avadel's Lumryz, a product for treating narcolepsy, projected to generate $265 million to $275 million in net revenues in 2025 [16] - The integration of Avadel is anticipated to create cost synergies and improve operational efficiency, aligning with Alkermes' ongoing development of alixorexton for narcolepsy [17]

Core Insights - Alkermes reported quarterly earnings of $0.49 per share, exceeding the Zacks Consensus Estimate of $0.42 per share, but down from $0.73 per share a year ago, representing an earnings surprise of +16.67% [1] - The company achieved revenues of $394.19 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.83% and up from $378.14 million year-over-year [2] - Alkermes has outperformed consensus EPS estimates three times in the last four quarters and has also topped revenue estimates three times during the same period [2] Earnings Outlook - The sustainability of Alkermes' stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.49 on revenues of $365.02 million, while the estimate for the current fiscal year is $1.85 on revenues of $1.42 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]